Virbagen Omega

RSS

interferon (omega)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 09/11/2018

Authorisation details

Product details
Name
Virbagen Omega
Agency product number
EMEA/V/C/000061
Active substance
recombinant omega interferon of feline origin
International non-proprietary name (INN) or common name
interferon (omega)
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QL03AB
Publication details
Marketing-authorisation holder
Virbac S.A.
Revision
11
Date of issue of marketing authorisation valid throughout the European Union
05/11/2001
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex
France

Product information

21/09/2018 Virbagen Omega - EMEA/V/C/000061 - IB/0009

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Dogs

Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.

Cats

Treatment of cats infected with feline leukaemia virus (FeLV) and / or feline immunodeficiency virus (FIV), in non-terminal clinical stages, from the age of nine weeks. In a field study conducted, it was observed that there was:

  • a reduction of clinical signs during the symptomatic phase (four months);
  • a reduction of mortality:
    • in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;
    • in non-anaemic cats, mortality rate of 50% in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.

Assessment history

How useful was this page?

Add your rating
Average
3 ratings
1 rating
4 ratings
2 ratings